My GLP-1 Provider Evidence Checklist: Price, Prescribing, Pharmacy, and Follow-Up

I’m Marcus Reid, and after years digging through clinical papers, COAs, and countless vendor pages, I’ve built a practical checklist I use every time I evaluate a GLP‑1 pathway for a friend or client. This is the exact evidence-first checklist I run through on price, prescribing, pharmacy, and follow-up — the parts vendors and flashy ads usually skip.

## Why I track vendors (and what the numbers tell me) I track 289 vendor profiles to see how common good documentation actually is. That volume matters: only 65 of those 289 (22%) publish named‑lab COAs, and right now only one vendor in my database has a published editorial assessment — that assessed vendor averages a 4.70/5 and clears my 4.5/5 quality threshold. Those figures tell me two things fast: (1) legitimate transparency is rare, and (2) when you see named labs and independent editorial reviews, it’s worth pausing to verify them.

## The S.A.F.E. Rx Check — my three‑step framework I use a compact, repeatable checklist I call the S.A.F.E. Rx Check. It’s short so I actually do it before I sign anything.

1. Source docs — Do they supply a named‑lab COA and a lot number that matches the product? (Yes/No) 2. Assessment — Is there an independent editorial review or clinician note in their profile? (Look for a 3rd‑party review, not just testimonials.) 3. Financial transparency — Is pricing shown as price per dose and total monthly cost? Are subscription, cancellation, and refund rules explicit? 4. Engagement & follow‑up — Do they offer scheduled clinical follow‑up, dose escalation plans, and an option to route prescriptions to my local pharmacy?

If a vendor fails any of those, I escalate my verification steps or walk away.

## Price: more than sticker shock — how I break it down I never pick a provider just because their per‑month number looks low. I break price into clear pieces:

- Base cost per dose and per mg — calculate weekly and monthly totals. - Add‑ons — telehealth subscription, labs, delivery, compounding fees. - Refill policy and auto‑ship — if they auto‑charge, can you pause or cancel without penalty? - Insurance and PA support — do they help file prior authorizations or provide documentation?

I’ll ask the clinician or platform for a sample invoice or estimate before committing. If they refuse, that’s a red flag. Price comparisons only make sense when you normalize to cost per effective dose and include administrative fees.

If you want a quick starting place, I use short tools to compare providers — try my /glp1-quiz to see which issues matter most for you, and then check /best-glp1 for an evidence‑oriented shortlist.

## Prescribing: what I look for in the clinical interaction A safe prescription isn’t a PDF; it’s a plan.

- Baseline labs and history: I expect documented A1c (for diabetes), renal function, pregnancy status for people of childbearing potential, and an explicit GI history. - Dose titration plan: Start dose, when to escalate, and what to do for GI side effects. - Prior authorization support: Will they prepare notes and engage your insurer? - Local pharmacy option: I prefer providers who will e‑prescribe to a retail pharmacy or reputable mail‑order pharmacy I choose.

I’m skeptical of platforms that handle prescribing completely in automated flows with no synchronous clinician time. That’s why a proper glp-1 telehealth comparison always weighs clinician availability and documented follow‑up against price—cheap + automated is a different product than clinician‑led care.

## Pharmacy and product origin: compound vs manufactured drugs One of the single most overlooked checks is origin. Is the prescription for a branded/manufactured GLP‑1 (e.g., from an approved manufacturer) or for a compounded product?

- If compounded: ask for named‑lab COAs tied to batch numbers and confirm the compounding pharmacy’s licensing and inspection history. - If manufacturer product: confirm NDC or lot numbers on the label and whether the pharmacy is a licensed dispensing pharmacy in your state.

I keep a running list in /vendors of pharmacies and the documentation styles they use. If a vendor can’t provide a verifiable lot number or the COA is a generic PDF with no lab stamp, I treat the product as unverifiable.

## Follow‑up: what separates good care from a subscription sale Follow‑up is the part most telehealth platforms underinvest in. I want:

- A scheduled follow‑up within 2–6 weeks of starting (for GI tolerability and dose checks). - Clear escalation criteria — who do I contact for severe nausea or signs of pancreatitis? - Lab schedule — when will A1c, kidney, and liver tests be rechecked? - A documented plan for discontinuation and rebound weight/biomarker management.

If a platform’s “follow‑up” is a chatbot or optional message board, I downgrade them. Clinical engagement matters to outcomes.

## A counter‑angle I don’t see enough people voice Most consensus advice right now is “go with the cheapest telehealth platform — it’s equivalent care.” I push back: if a platform hides pharmacy origin, refuses to e‑prescribe to your local pharmacy, or publishes no named‑lab COAs, cost savings could be traded for product opacity. Cheaper plans often rely on opaque compounding or overseas supply chains. I’d rather pay more for transparent sourcing, explicit clinician involvement, and a clear escalation pathway.

## A quick evidence‑tracking mini‑table I use | Question | My evidence check | |---|---| | COA present? | Named lab + lot match | | Clinical review? | Editorial or clinician note | | Price details? | Per dose + monthly total | | Pharmacy? | Local e‑prescribe option |

(Short and practical — this table is what I run down verbally during first contact.)

## Final practical tips from my desk - Ask for the COA and lot number before paying. Then independently check the lab’s name and accreditation. - Normalize price to weekly effective dose, not monthly sticker. - Insist on e‑prescribe to your pharmacy. If they push only their ship‑per‑month solution, ask why. - Keep a written dose escalation plan and a copy of any prior‑authorization paperwork. - Use my /glp1-quiz to clarify your priorities before you compare platforms; when you look at vendors, my /best-glp1 list is where I start my deeper checks.

*This is how I cut through marketing and sales scripts to the evidence and paperwork that matter. If a provider can’t or won’t answer these specific, document‑based questions, I treat them as high‑risk and move on.*

*For informational purposes only — not medical advice. Consult a licensed healthcare provider before starting, changing, or obtaining a GLP‑1 medication.*

Frequently asked questions

References

1. PubMed literature search: glp-1 provider checklist
2. ClinicalTrials.gov search

About the author

Marcus Reid: Marcus Reid spent a decade in software engineering before going deep into peptide research, product documentation, and the clinical literature. He writes about what the data and the paperwork actually say. He is not a doctor; PeptideTally content is educational and does not constitute medical advice.